Perspectives on Aducanumab Approval (Neurology Recall August 2021)
This month's replay of past episodes showcases a selection of interviews concerning the FDA approval of aducanumab for the treatment of Alzheimer disease from clinical, political, and economic perspec...
1 Elo 20211h 28min
Impact of Thymectomy on Myasthenia Gravis Remission
Dr. Stacey Clardy discusses the impact of surgical approaches to thymectomy upon remission rates in myasthenia gravis with Dr. Joseph Shrager.
26 Heinä 202116min
Symptoms and Incidence of RCVS; Optimizing Stroke Prevention in Atrial Fibrillation
In the first segment, Will Rondeau discusses the symptoms, incidence, and resource utilization of reversible cerebrovascular vasoconstriction syndrome with Dr. Jessica Magid-Bernstein. In the second p...
19 Heinä 202125min
Illness in Overseas U.S. Embassies Employees; Afferent Baroreflex Failure
In the first segment, Dr. Alex Menze talks with Dr. Clifford Saper about Havana Syndrome and recent attacks on American diplomats. In the second part of the podcast, Dr. Jeff Ratliff discusses the nat...
12 Heinä 202129min
Evaluations in First Episode Psychosis; Dr. Daniel Gibbs on his Battle with Alzheimer's
In the first segment, Dr. Gregg Day speaks with Dr. Josep Dalmau about NMDAR antibodies in patients with first episode psychosis and the utility of criteria for autoimmune psychosis. In the second par...
5 Heinä 202131min
Management of Neurologic Conditions in Pregnancy (Neurology Recall July 2021)
This month's replay of past episodes showcases a selection of interviews on the impact of pregnancy on various neurologic disorders, featuring Drs. Page Pennell, Paula Emanuela Voinescu, Mary Angela O...
1 Heinä 20211h 19min
SPECIAL REPORT: A Discussion with Mary Post (Part 2)
This second installment in our two-part series features Dr. Stacey Clardy in conversation with Mary Post, CEO of the American Academy of Neurology.
28 Kesä 202112min
SPECIAL REPORT on Aducanumab Approval: A Pulitzer Prize-winning Journalist's Perspective
Dr. Gregg Day speaks with Pam Belluck, an award-winning journalist at the New York Times, about her coverage of the recent FDA approval of aducanumab for Alzheimer disease treatment.
24 Kesä 202131min
